Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Sinovent logo — Pioneering advanced treatment solutions with a focus on inno...

Sinovent

Pioneering advanced treatment solutions with a focus on innovation, driven by a robust biotechnology platform and extensive management experience.

Founded 2017 Series E Total: $1.70B Biotechnology, Life Sciences

General Information

Company Name Sinovent
Founded Year 2017
Industries Biotechnology, Life Sciences
Funding Stage Series E
Social

BounceWatch is an independent company data service, not affiliated with Sinovent. To contact Sinovent, visit evopointbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Sinovent

Sinovent is a pioneering global biopharmaceutical company that was established in 2016. With a focus on innovation, the company is dedicated to developing advanced treatment solutions for global healthcare challenges. Leveraging a robust biotechnology platform and substantial financial backing, Sinovent has emphasized global standard excellence since its inception. The company's extensive management experience and integration of expertise in science, management, and finance set it apart in the biotechnology industry. Currently, Sinovent has 12 products in development, primarily targeting oncology, auto-immune diseases, and infectious diseases. The most recent investment in Sinovent was a CNY700.00M Series E investment on 20 February 2024. This investment was made by a consortium of notable investors, including Loyal Valley Capital, Tsinghua Holdings Capital, Sea of Stars Capital, Zhuopu Capital, 上海浦东创业投资有限公司, Guoxin Investment, Jinan Industrial Development Group, Tencent, and Guangdong Development Capital. Overall, Sinovent showcases significant potential in the biotechnology industry, with its focus on innovation, diverse therapeutic pipeline, and the backing of prominent investors.

Taxonomy: biopharmaceutical, innovation, global standard excellence, management experience, financial backing, oncology, auto-immune diseases, infectious diseases, healthcare challenges, science expertise, advanced treatment methods, Sinovent, global, drug development

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series E CNY700.00M 10
Loyal Valley Capital Tsinghua Holdings Capital Apricot Capital
Loyal Valley Capital, Tsinghua Holdings Capital +8
20 Feb 2024
Venture Round Undisclosed -
31 Dec 2020
Series C CNY1.00B -
25 Aug 2020
Series A Undisclosed -
01 May 2018

Sinovent Alternatives & Competitors

View All Alternatives
Sinovent vs
ImmunoGenesis, Inc.
ImmunoGenesis, Inc. United States

Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mechanisms of...

Venture round
14 employees
Biotechnology, Health Care
Sinovent vs
ImCheck Therapeutics
ImCheck Therapeutics France

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic

Grant
57 employees
Biopharma, Biotechnology
Sinovent vs
Eikon Therapeutics
Eikon Therapeutics United States

Eikon is a late-stage clinical biopharmaceutical company dedicated to inventing and developing break...

Series D
429 employees
Biotechnology, Health Care
View all alternatives

FAQ About Sinovent

Pioneering advanced treatment solutions with a focus on innovation, driven by a robust biotechnology platform and extensive management experience.
Sinovent was founded in 2017.
Sinovent operates in Biotechnology and Life Sciences. Its work centres on biopharmaceutical, innovation, global standard excellence and management experience.
Sinovent has completed 4 funding rounds, raising a total of $1.70B. The latest funding stage is Series E.
Top alternatives and competitors to Sinovent include ImmunoGenesis, Inc., ImCheck Therapeutics, Eikon Therapeutics, Treeline, Taiga Biotechnologies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Sinovent and ImmunoGenesis, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Sinovent, https://bouncewatch.com/company/sinovent, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes